Healthcare
Northwest Biotherapeutics, Inc.(NWBO)
Live Price
Offline$0.1988
+4.85% today
1Y Change
-24.16%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $320.00M
- Revenue Growth
- -0.3%
- EPS Growth
- +38.5%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Northwest Biotherapeutics, Inc. (NWBO) is a Healthcare stock with a market cap of $320.00M and listed on OTC. The stock last traded around $0.20 and down 24.2% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -0.3%, EPS growth of +38.5%, a dividend yield of 0.0%. What stands out right now is revenue -0.3%, EPS +38.5%, free cash flow +20.3% with operating margin -4347.9% and ROIC -184.8%. Valuation already assumes a fairly strong business story at price/sales 233.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines NWBO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-0.3% vs +7.6% peer median
Operating Margin
Below sector median
-4347.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -0.3% and EPS is at +38.5%, with operating margin around -4347.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -3.8% | -3.8% | -26.9% |
2026 Apr 14, 2026 | โ | +0.0% | -5.0% | +25.0% |
2025 Nov 14, 2025 | โ | -4.2% | +4.2% | +0.0% |
Benchmark Edge
NWBO vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NWBO
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NWBO Max Drawdown
-40.75%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NWBO and SPY.
Company Overview
Northwest Biotherapeutics, Inc.
Other OTC
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
- Leadership
- Linda F. Powers
- IPO Date
- Dec 14, 2001
- Employees
- 25
- Street Address
- 4800 Montgomery Lane
- Mailing
- Bethesda, MD, 20814
- Region
- Bethesda, MD, US
- Reporting Currency
- USD
- Investor Line
- 240 497 9024
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 233.2
- Price/Book
- โ
Growth
- Revenue
- -0.3%
- EPS
- +38.5%
- Free Cash Flow
- +20.3%
Profitability
- Gross Margin
- 4.1%
- Operating Margin
- -4347.9%
- Net Margin
- -4385.1%
- ROE
- 70.5%
- ROIC
- -184.8%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.06
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.